Contribution: Industrial Research Assistance Program – Contributions to Firms
SolAeroMed Inc.
$50,000.00
Proof of concept of new drug therapy for Cystic Fibrosis
FY 2018-19 · 2019-02-15
Summary
SolAeroMed Inc is developing respiratory based technologies spun out of the University of Calgary. The project will support a proof of concept study to evaluate the firm's lead drug S1226 in Cystic Fibrosis (CF).
Department
Program
Industrial Research Assistance Program – Contributions to FirmsIndustrial Research Assistance Program-Contributions to Firms (linked with high confidence)
Recipient
Location
Calgary|Calgary, Alberta, Canada
Recipient Type
For-profit organization
Business Number
829682111
Type
Contribution
Source
Proactive Disclosure - Grants and Contributions
As published
Agreement End Date
2020-01-31
Agreement Number
924681
Agreement Start Date
2019-02-15
Agreement Title
Proof of concept of new drug therapy for Cystic Fibrosis
Agreement Title (French)
Démonstration de faisabilité d'un nouveau traitement médicamenteux contre la fibrose kystique
Agreement Type
Contribution
Agreement Value
$50,000.00
Amendment Number
0
Coverage
IRAP Contributions to Firms projects stimulate wealth creation for Canada through technological innovation. | Les projets des Contributions aux entreprises stimulent la création de richesse au Canada grâce à l’innovation technologique.
Description
SolAeroMed Inc is developing respiratory based technologies spun out of the University of Calgary. The project will support a proof of concept study to evaluate the firm's lead drug S1226 in Cystic Fibrosis (CF).
Description (French)
SolAeroMed Inc. est en train de développer des technologies respiratoires provenant de l'Université de Calgary. Le projet appuiera une étude de démonstration de faisabilité visant à évaluer le principal médicament de l'entreprise, le S1226, dans la fibrose kystique (FK).
Expected Results
The purpose of IRAP Contributions to Firms is to support research, development, adoption and/or adaptation of innovative or technology-driven new or improved products, services or processes in Canada up to their commercialization
Expected Results (French)
Le PARI, par le biais des Contributions aux entreprises, vise à appuyer la recherche, le développement, l’adaptation et/ou l’adoption au Canada de produits, de services ou de processus novateurs ou axés sur des technologies nouvelles ou améliorées, et ce jusqu’à leur commercialisation
Federal Riding
Calgary Centre
Federal Riding (French)
Calgary-Centre
Federal Riding Number
48004
NAICS Code
325410
Organization Code
nrc-cnrc
Organization
National Research Council Canada | Conseil national de recherches Canada
Program Name
Industrial Research Assistance Program – Contributions to Firms
Program Name (French)
Programme d’aide à la recherche industrielle – Contributions aux entreprises
Program Purpose
The purpose of IRAP Contributions to Firms is to support research, development, adoption and/or adaptation of innovative or technology-driven new or improved products, services or processes in Canada up to their commercialization
Program Purpose (French)
Le PARI, par le biais des Contributions aux entreprises, vise à appuyer la recherche, le développement, l’adaptation et/ou l’adoption au Canada de produits, de services ou de processus novateurs ou axés sur des technologies nouvelles ou améliorées, et ce jusqu’à leur commercialisation
Recipient Business Number
829682111
Recipient City
Calgary|Calgary
Recipient Country
CA
Recipient Legal Name
SolAeroMed Inc.
Recipient Postal Code
T3E 6L1
Recipient Province or Territory
AB
Recipient Type
F
Reference Number
172-2018-2019-Q4-924681
